Search

Search Results

• Biologics and small molecules treatment for moderate-to-severe atopic dermatitis patients with comorbid conditions and special populations: an Italian perspective

  Alba Guglielmo, Maria Ludovica Deotto , Luigi Naldi , Giuseppe Stinco, Alessandro Pileri, Bianca Maria Piraccini, Anna Belloni Fortina, Andrea Sechi

  13-09-2023

  https://doi.org/10.4081/dr.2023.9839

  2288

  PDF: 857

  HTML: 26

• Nightmares caused by isotretinoin in treating hidradenitis suppurativa: a case report and clinical insights

  Fawaz Aljehani, Shumukh Alqahtani, Sara Alharbi, Seham Alsulami

  06-12-2024

  https://doi.org/10.4081/dr.2024.10171

  1026

  PDF: 276

  HTML: 4
• 

  Anti-interleukin-17 and anti-interleukin-23 biologic drugs for genital psoriasis: a single-center retrospective comparative study

  Andrea Cortese, Luigi Gargiulo, Luciano Ibba, Giovanni Fiorillo, Francesco Toso, Carlo Alberto Vignoli, Alessandra Narcisi, Antonio Costanzo, Mario Valenti

  19-05-2023

  https://doi.org/10.4081/dr.2023.9692

  918

  PDF: 470

  HTML: 17

• Tildrakizumab in the treatment of plaque psoriasis in an HIV+ patient: a case report and literature review of anti-interleukin drugs

  Viviana Lora, Dario Graceffa, Monia Di Prete, Carlo Cota

  11-11-2024

  https://doi.org/10.4081/dr.2024.10140

  727

  PDF: 372

  SUPPLEMENTARY MATERIAL: 75

  HTML: 4
• 

  Erythrodermic psoriasis treated with apremilast

  John Arcilla, Daniel Joe, Johnathan Kim, Yohanan Kim, VuAnh N. Truong, Navin Jaipaul

  19-09-2016

  https://doi.org/10.4081/dr.2016.6599

  1957

  PDF: 880

  HTML: 597
• 

  Real-world use of dimethyl fumarate in patients with plaque psoriasis: a Delphi-based expert consensus

  Martina Burlando, Elena Campione, Aldo Cuccia, Giovanna Malara, Luigi Naldi, Francesca Prignano, Leonardo Zichichi

  29-12-2022

  https://doi.org/10.4081/dr.2023.9613

  1640

  PDF: 450

  HTML: 72

• Natural language processing of online support group postings reveals patients’ perspectives on strategies for managing psoriasis

  Karan Rajalingam, Phillip M. Johansen, Nicole J. Levin, Jerry Qi, Oge Marques

  11-09-2023

  https://doi.org/10.4081/dr.2023.9824

  780

  PDF: 441

  HTML: 25

• Treatment satisfaction among patients with psoriasis in Saudi Arabia

  Mahdi Aldhafiri, Rahaf Almutairi, Reem Albejais, Asma Almubark, Hussain Alwesaibie, Mohammed Albesher, Manayer Almustihi

  15-04-2024

  https://doi.org/10.4081/dr.2024.9967

  831

  PDF: 440

  HTML: 18
• 

  Mortality risk factors in febrile ulceronecrotic Mucha- Habermann disease: a systematic review of therapeutic outcomes and complications

  Vasiliki Tasouli-Drakou, May Nguyen, Hannah Guinn, Omron Hassan, Sneha Butala, Sheshanna Phan

  21-11-2022

  https://doi.org/10.4081/dr.2022.9492

  1578

  PDF: 608

  HTML: 81

• Anisakis simplex and urticaria. What we know about its real incidence and management in dermatological settings?

  Sanja Javor, Donatella Bignardi, Matteo Borro, Cesare Massone

  29-08-2023

  https://doi.org/10.4081/dr.2023.9819

  937

  PDF: 611

  HTML: 13
• 

  Long term efficacy, safety, and tolerability of tildrakizumab in epileptic patient with psoriasis and eczema

  Nicoletta Bernardini, Nevena Skroza, Giovanni Rossi, Alessandra Mambrin, Ersilia Tolino, Federica Marraffa, Martina Caviglia, Antonio Di Guardo, Salvatore Volpe, Ilaria Proietti, Concetta Potenza

  21-11-2022

  https://doi.org/10.4081/dr.2022.9447

  1207

  PDF: 352

  HTML: 39
• 

  Real-world treatment patterns, patient-reported outcomes, and effectiveness of flexible-dosing etanercept in patients with plaque psoriasis in Greece

  Dimitris Rigopoulos, Aikaterini Patsatsi, Christina Antoniou, Dimitrios Sotiriadis, Angeliki Roussaki-Schulze, Nadia Boubouchairopoulou, Ioannis Skiadas, Vasillios Tsekouras, Ana Cristina Hernandez Daly

  21-11-2022

  https://doi.org/10.4081/dr.2022.9265

  1412

  PDF: 372

  HTML: 21
• 

  Lentiginous eruption in resolving psoriasis plaques during treatment with ixekizumab: a case report and review of the literature

  Pablo Santa María, Fernando Valenzuela, Claudia Morales, Raul De la Fuente, Roberto Cullen

  11-10-2017

  https://doi.org/10.4081/dr.2017.7079

  1232

  PDF: 592

  HTML: 138

• Skin-directed therapy and biologic response modifiers in mycosis fungoides

  Vieri Grandi, Virginia Alba Colantuono, Nicola Pimpinelli

  07-05-2024

  https://doi.org/10.4081/dr.2024.9926

  486

  PDF: 480

• Efficacy and safety of adalimumab biosimilar GP2017 in a 24-month treatment period for plaque psoriasis: real-life experience from Emilia-Romagna centers, Italy

  Marco May Lee, Vito Di Lernia, Francesca Peccerillo, Federico Bardazzi, Michela Tabanelli, Michela Ricci, Davide Melandri, Monica Corazza, Francesca Satolli, Andrea Conti

  01-07-2025

  https://doi.org/10.4081/dr.2025.10315

  227

  PDF: 52
• 

  Environmental factors in autoimmune bullous diseases with a focus on seasonality: new insights

  Roberto D'Astolto, Lavinia Quintarelli, Alberto Corrà, Marzia Caproni, Luca Fania, Giovanni Di Zenzo, Biagio Didona, Giulia Gasparini, Emanuele Cozzani, Claudio Feliciani

  14-06-2023

  https://doi.org/10.4081/dr.2023.9641

  830

  PDF: 426

  HTML: 17

• Efficacy and safety of risankizumab in patients with erythrodermic and sub-erythrodermic psoriasis: a case series

  Andrea D'Arino, Maria Concetta Fargnoli, Pasquale Frascione, Chiara Assorgi, Annunziata Dattola, Viviana Lora, Matteo Megna, Flavia Pigliacelli, Emanuele Vagnozzi, Diego Orsini

  30-07-2025

  https://doi.org/10.4081/dr.2025.10379

  21

  PDF: 10
• 

  The first reported case of erythrodermic sarcoidosis with systemic involvement during COVID-19 vaccination

  Georgi Tchernev, Simona Kordeva, Heily Kirilova, Valentina Broshtilova

  01-03-2023

  https://doi.org/10.4081/dr.2023.9636

  1110

  PDF: 538

  HTML: 62

• Acute generalized exanthematous pustulosis triggered by dupilumab

  Caterina Mariarosaria Giorgio, Gaetano Licata, Giuseppe Argenziano, Vittorio Tancredi, Anna Balato, Eugenia Veronica Di Brizzi

  23-07-2025

  https://doi.org/10.4081/dr.2025.10219

  131

  PDF: 51
• 

  Late reaction to ustekinumab infusion

  Marina Resener Morais, Luana Pizarro Meneghello, Carina Flores de Oliveira, André Vicente Esteves Carvalho

  e2

  09-09-2013

  https://doi.org/10.4081/dr.2013.e2

  3832

  PDF: 613

  HTML: 259
• 

  Guselkumab for the treatment of severe plaque psoriasis in a schizophrenia patient

  Nicoletta Bernardini, Nevena Skroza, Elisabeth Prevete, Federica Marraffa, Ilaria Proietti, Ersilia Tolino, Alessandra Mambrin, Giovanni Rossi, Salvatore Volpe, Giuseppe Bersani, Concetta Potenza

  23-11-2022

  https://doi.org/10.4081/dr.2022.9476

  1262

  PDF: 420

  HTML: 23
• 

  Photocarcinogenicity of selected topically applied dermatological drugs: calcineurin inhibitors, corticosteroids, and vitamin D analogs

  Catharina Margrethe Lerche, Hans Christian Wulf

  e13

  14-09-2010

  https://doi.org/10.4081/dr.2010.e13

  1990

  PDF: 768

  HTML: 164
• 

  A case of squamous cell carcinoma arising in a giant porokeratosis previously diagnosed as psoriasis

  Lorry Aitkens, Joel Byrne, Charay Jennings-Dover, Kathryn Anne Potter

  29-12-2022

  https://doi.org/10.4081/dr.2023.9634

  835

  PDF: 391

  HTML: 110

• Severe paradoxical generalized pustular psoriasis induced by adalimumab biosimilar successfully treated with brodalumab

  Angela Fico, Edoardo Mortato, Claudia Paganini, Marina Talamonti, Cosimo Di Raimondo, Dionisio Silvaggio, Luca Bianchi, Marco Galluzzo

  30-05-2025

  https://doi.org/10.4081/dr.2025.10414

  263

  PDF: 141
• 

  Measuring the impact of pruritus in patients with epidermolysis bullosa: evaluation with an itch-specific instrument

  Ashjan Alheggi, Raneem Alnutaifi, Manal Alkhonezan, Norah Almudawi, Renad Alsuhaibani, Philip Moons, Turki Aljuhani

  18-05-2023

  https://doi.org/10.4081/dr.2023.9700

  1063

  PDF: 303

  APPENDIX S1: 122

  HTML: 6